Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.49 |
| ▸ | MET | P08581 | 7/20 | 0.49 |
| ▸ | FLT1 | P17948 | 3/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | PLK4 | O00444 | 1/20 | 0.37 |
| ▸ | GAK | O14976 | 1/20 | 0.37 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.37 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.37 |
| ▸ | STK10 | O94804 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6751167 | 1.00 | KDR (0.49) | KDRMETFLT1PDGFRBCYP3A4 | |
| SCHEMBL6751165 | 0.86 | KDR (0.45) | KDRMETFLT1PDGFRBPLK4 | |
| SCHEMBL5837590 | 0.84 | KDR (0.51) | KDRMETFLT1ADORA3ADORA2A | |
| SCHEMBL5837584 | 0.84 | KDR (0.51) | KDRMETFLT1ADORA3ADORA2A | |
| SCHEMBL5838484 | 0.84 | KDR (0.51) | KDRMETFLT1ADORA3ADORA2A | |
| SCHEMBL6749082 | 0.84 | KDR (0.43) | KDRMETFLT1PDGFRBCYP3A4 | |
| SCHEMBL5771628 | 0.83 | KDR (0.52) | KDRMETFLT1MST1RADORA3 | |
| SCHEMBL6751074 | 0.82 | KDR (0.48) | KDRMETFLT1MST1RADORA3 | |
| SCHEMBL6747106 | 0.82 | KDR (0.48) | KDRMETFLT1MST1RADORA3 | |
| SCHEMBL6751075 | 0.82 | KDR (0.48) | KDRMETFLT1MST1RADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6833456-B2 | Heterocyclic sulfides such as 5-(2-(2R-Hydroxymethyl-pyrrolidine-1-carbonyl)-thieno(3,2-b)pyridin-7 -ylamino)-2-methyl-indole-1-carboxylic acid methylamide, used as angiogenesis inhibitors | AGOURON PHARMACEUTICALS, INC. | 2004-12-21 | — | — | US | disclosed |
| US-20040019065-A1 | Indolyl-urea derivatives of thienopyridines useful as antiangiogenic agents, and methods for their use | ROMINES WILLIAM HENRY (US) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019065-A1 | Indolyl-urea derivatives of thienopyridines useful as antiangiogenic agents, and methods for their use | CDKN1A, CCNA1, TYMP | KDR 62/4885MET 2583/4885FLT1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.